Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

(NASDAQ:IONS) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome (AS), a rare neurological disease that often presents in infancy and is characterized by profound intellectual disability, impaired communication, motor impairment and debilitating seizures. “With no approved disease-modifying treatments available for people liv